ISEE — IVERIC bio Share News
0.000.00%
Last trade - 00:00HealthcareAdventurousLarge Cap
Brief: Iveric Bio Announces Vision Loss Reduction Data In Geographic Atrophy From Avacincaptad Pegol Gather Trials
Brief: Iveric Bio Reports Fourth Quarter And Full Year 2022 Operational Highlights And Financial Results
Brief: IVERIC bio reports Q4 net loss of USD 59.061 million.
Iveric Bio Inc Expected To Post A Loss Of 37 Cents A Share: Earnings Preview
U.S. RESEARCH ROUNDUP-American Express, Caleres, Splunk
Iveric Bio Inc Expected To Post A Loss Of 37 Cents A Share: Earnings Preview
U.S. STOCKS ON THE MOVE-U.S. banks, lithium miners, gold miners
Iveric bio jumps as FDA grants priority review to eye disorder drug
Brief: Iveric Bio Announces FDA Accepts New Drug Application And Grants Priority Review For Avacincaptad Pegol For The Treatment Of Geographic Atrophy
Brief: Iveric Bio Appoints Pravin Dugel To Its Board Of Directors
Brief: IVERIC Bio Announces Completion Of Rolling NDA Submission To FDA For Avacincaptad Pegol
Brief: Iveric Bio Borrows The Full $50 Million Tranche Of Term Loan Advances Available At The Company’S Election
U.S. STOCKS ON THE MOVE-Silver miners, PVH Corp, energy firms
U.S. STOCKS ON THE MOVE-Gold miners, Kroger, Dollar General, Nutanix
U.S. STOCKS ON THE MOVE-Nutanix, Okta, Splunk
Iveric Bio dips on upsized $300 mln share offering
Brief: Iveric Bio Announces Pricing Of $300 Mln Public Offering Of Common Stock
Iveric Bio slips on $250 mln stock offering launch
Brief: Iveric Bio Announces Proposed Offering Of Common Stock